Coeptis VP exercises options, granted 20K shares

Coeptis Therapeutics Holdings, Inc. director and VP of Operations Daniel Alexander Yerace reported acquiring common stock on February 11, 2026.

Accepted by SEC EDGAR 02/13/2026 - 05:00 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Coeptis Therapeutics Holdings, Inc. director and VP of Operations Daniel Alexander Yerace reported acquiring common stock on February 11, 2026. He obtained 10,000 shares through the exercise of stock options at a weighted average price of $10.41 per share. He also received a grant of 20,000 restricted shares issued in connection with an option exchange program in which he surrendered underwater options for restricted stock. Following these transactions, he directly beneficially owned 70,531 shares of Coeptis common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Yerace Daniel Alexander

Role VP Operations

Type	Security	Shares	Price	Value
Exercise	Common stock	10,000	$10.41	$104K
Grant/Award	Common Stock	20,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 70,531 shares (Direct)

Footnotes (2)

1. F1. Represents the weighted average exercise price of shares purchased upon exercise of stock options.
2. F2. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did COEP executive Daniel Yerace report?

Daniel Alexander Yerace reported acquiring Coeptis common stock. He exercised stock options for 10,000 shares at a weighted average price of $10.41 and received a grant of 20,000 restricted shares through an option exchange program, bringing his direct holdings to 70,531 shares.

How many Coeptis (COEP) shares does Daniel Yerace own after these transactions?

After the reported transactions, Daniel Alexander Yerace beneficially owns 70,531 shares of Coeptis common stock directly. This figure reflects both the 10,000 shares acquired via option exercise and the 20,000 restricted shares granted through the option exchange program on February 11, 2026.

What was the price for Daniel Yerace’s Coeptis option exercise?

The 10,000 Coeptis shares acquired by Daniel Alexander Yerace through option exercise had a weighted average exercise price of $10.41 per share. This price represents the aggregate average cost of the stock options he exercised on February 11, 2026, as disclosed in the filing.

What is the nature of the 20,000-share grant to COEP’s Daniel Yerace?

The 20,000 Coeptis shares were granted as restricted stock at a per-share price of $0. They were issued in connection with an option exchange program, in which Daniel Alexander Yerace surrendered underwater stock options in exchange for this restricted stock grant.

What roles does Daniel Yerace hold at Coeptis Therapeutics (COEP)?

Daniel Alexander Yerace is both a director and an officer at Coeptis Therapeutics Holdings, Inc., serving as VP Operations. His dual role as director and executive officer is explicitly indicated in the insider ownership section of the Form 4 filing.

Were Daniel Yerace’s COEP transactions open-market purchases or equity awards?

The disclosed transactions were equity-related awards rather than open-market purchases. Daniel Alexander Yerace exercised stock options to acquire 10,000 shares and received 20,000 restricted shares through an option exchange program where underwater options were surrendered for restricted stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yerace Daniel Alexander

(Last) (First) (Middle)

105 BRADFORD RD, SUITE 420

(Street)

WEXFORD PA 15090

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coeptis Therapeutics Holdings, Inc. [ COEP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP Operations

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	02/11/2026		M		10,000	A	$10.41(1)	70,531	D
Common Stock	02/11/2026		A		20,000	A	$0(2)	70,531	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average exercise price of shares purchased upon exercise of stock options.

2. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

	/s/ Daniel A. Yerace	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.